Saltar al contenido
MilliporeSigma
Todas las fotos(1)

Documentos

P-011

Supelco

(+)-Propoxyphene solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C22H29NO2
Número de CAS:
469-62-5
Peso molecular:
339.47
UNSPSC Code:
41116107
PubChem Substance ID:
329820017
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

CCC(=O)O[C@@](Cc1ccccc1)([C@H](C)CN(C)C)c2ccccc2

InChI

1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1

InChI key

XLMALTXPSGQGBX-GCJKJVERSA-N

Gene Information

human ... OPRM1(4988)

General description

A certified Snap-N-Spike® solution standard suitable for propoxyphene testing methods by GC/MS or LC/MS in pain prescription monitoring, clinical toxicology, urine drug testing, or forensic analysis. Propoxyphene, also known as dextropropoxyphene, is an opioid analgesic drug intended for treatment of mild pain. In combination with either paracetamol or aspirin, dextropropoxyphene is sold under trade names including Darvocet-N® and Darvon®.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Darvocet-N is a registered trademark of AAIPharma LLC
Darvon is a registered trademark of Xanodyne Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

FlameExclamation mark
GHS02,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

35.6 °F - closed cup

flash_point_c

2 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Suicides involving co-proxamol fell dramatically after withdrawal in UK.
Zosia Kmietowicz
BMJ (Clinical research ed.), 344, e3255-e3255 (2012-05-11)
Margareeta Häkkinen et al.
Forensic science international, 222(1-3), 327-331 (2012-08-14)
There is a rising trend of fatal poisonings due to medicinal opioids in several countries. The present study evaluates the drug and alcohol findings as well as the cause and manner of death in opioid-related post-mortem cases in Finland from
W Stephen Waring et al.
Clinical toxicology (Philadelphia, Pa.), 49(6), 452-456 (2011-08-10)
The Medicines and Healthcare products Regulatory Authority (MHRA) is the government body with responsibility for regulating new and existing medicines and medical devices in the United Kingdom. The Yellow Card scheme is a well-established pharmacovigilance system that collects voluntary reports
Robert B Raffa et al.
Expert opinion on pharmacotherapy, 13(10), 1397-1409 (2012-05-10)
d-Propoxyphene, which was previously available in many single-agent and combination products, was recently voluntarily withdrawn from the US market following an FDA recommendation based partly on the concern that the risk associated with QT prolongation exceeded the clinical benefit of
Yatan Pal Singh Balhara et al.
Journal of opioid management, 8(1), 45-49 (2012-04-07)
In view of increasing safety concerns, there is a need to assess benefits of use of dextropropoxyphene as opioid substitution treatment, if any. This study aims at urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico